Propionyl-L-carnitine versus pentoxifylline: Improvement in walking capacity in patients with intermittent claudication

Clinical Drug Investigation

Volumn 22, Issue , 2002, Pages 1-6

  Strano, Antonio ^a  

^a Ctro Stud Malat Vasc/Ateroscle   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PROPIONYLCARNITINE;

ADULT; AGED; ANGINA PECTORIS; ANKLE PRESSURE; ARTICLE; BLOOD EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPIGASTRIC PAIN; EXERCISE; FEMALE; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; INTESTINE INFARCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREADMILL; TREATMENT OUTCOME; TREATMENT PLANNING; WALKING;

EID: 0036214126     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222001-00001     Document Type: Article

References (27)

1. Basic data related to the natural history of intermittent claudication
2. The epidemiology of peripheral arterial disease
3. Die medicamentöse behandlung von obliterierenden prozessen der peripheren arteriopathien
4. Clinical evaluation of the effect of pentoxifylline in patients with chronic peripheral circulatory disorders
5. Double-blind, cross-over study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs
6. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
7. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease: Scandinavian Study Group
8. The effects of pentoxifylline on patients with intermittent claudication
9. Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity
10. Propionyl-L-carnitine: Biochemical significance and possible role in cardiac metabolism
11. The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria
12. Muscle carnitine deficiency in patients with severe peripheral vascular disease
13. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: Effect of propionyl-L-carnitine
14. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study
15. Effect of propionyl-L-carnitine on quality of life in intermittent claudication
16. European multicenter study on propionyl-L-carnitine in intermittent claudication
17. Assessment of peripheral vascular disease in diabetes: Report and recommendations of an international workshop sponsored by the American Diabetes Association and the American Heart Association
18. Multicenter clinical trials: Bradford Hill's contributions and some subsequent developments
19. Pyruvate-dehydrogenase complex: Meticulous regulator of glucose disposal in animals
20. Possible functions of short-chain and medium-chain carnitine acyltransferase
21. Increase in walking distance in patients with peripheral vascular disease treated with L-carnitine: A double-blind, cross-over study
22. Pyruvate carboxylase and propionyl-CoA carboxylase as anaplerotic enzymes in skeletal muscle mitochondria
23. Anaplerotic effect of propionyl carnitine in rat heart mitochondria
24. Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: A functional, histologic, and NMR spectroscopic study
25. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials, 1965-1985
26. Conservative management of intermittent claudication
27. Pharmacological approaches to the treatment of intermittent claudication